- Home
- RDCM vs PLX Comparison
RDCM vs PLX Comparison
Compare RDCM & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDCM
- PLX
- Stock Information
- Founded
- RDCM 1985
- PLX 1993
- Country
- RDCM Israel
- PLX United States
- Employees
- RDCM N/A
- PLX N/A
- Industry
- RDCM Computer peripheral equipment
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RDCM Technology
- PLX Health Care
- Exchange
- RDCM Nasdaq
- PLX Nasdaq
- Market Cap
- RDCM 203.7M
- PLX 204.9M
- IPO Year
- RDCM 1997
- PLX 1998
- Fundamental
- Price
- RDCM $13.82
- PLX $2.15
- Analyst Decision
- RDCM Strong Buy
- PLX Strong Buy
- Analyst Count
- RDCM 1
- PLX 1
- Target Price
- RDCM $18.00
- PLX $15.00
- AVG Volume (30 Days)
- RDCM 52.5K
- PLX 1.1M
- Earning Date
- RDCM 11-12-2025
- PLX 11-13-2025
- Dividend Yield
- RDCM N/A
- PLX N/A
- EPS Growth
- RDCM 79.61
- PLX N/A
- EPS
- RDCM 0.56
- PLX 0.08
- Revenue
- RDCM $66,334,000.00
- PLX $61,948,000.00
- Revenue This Year
- RDCM $18.07
- PLX $14.53
- Revenue Next Year
- RDCM $11.52
- PLX $75.77
- P/E Ratio
- RDCM $23.90
- PLX $24.02
- Revenue Growth
- RDCM 18.18
- PLX 62.79
- 52 Week Low
- RDCM $9.81
- PLX $1.01
- 52 Week High
- RDCM $15.98
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- RDCM 47.65
- PLX 48.79
- Support Level
- RDCM $13.05
- PLX $1.60
- Resistance Level
- RDCM $14.16
- PLX $2.55
- Average True Range (ATR)
- RDCM 0.55
- PLX 0.16
- MACD
- RDCM -0.09
- PLX -0.06
- Stochastic Oscillator
- RDCM 37.16
- PLX 51.18
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.